Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Spring Sale
Enjoy this offer
* See conditions under "Our services"

Valuation: Betta Pharmaceuticals Co., Ltd.

Capitalization 1.83TCr 264.69Cr 228.32Cr 206.18Cr 197.59Cr 359.12Cr 24TCr 375.49Cr 2.43TCr 976.17Cr 12TCr 993.61Cr 972.25Cr 42TCr P/E ratio 2025 *
32x
P/E ratio 2026 * 21.9x
Enterprise value 1.97TCr 284.95Cr 245.79Cr 221.96Cr 212.72Cr 386.61Cr 26TCr 404.22Cr 2.62TCr 1.05TCr 13TCr 1.07TCr 1.05TCr 45TCr EV / Sales 2025 *
5.48x
EV / Sales 2026 * 4.54x
Free-Float
51.51%
Yield 2025 *
0.83%
Yield 2026 * 1.06%
1 day-1.27%
1 week-5.54%
Current month-5.54%
1 month-7.94%
3 months-9.97%
6 months-39.48%
Current year-6.94%
1 week 41.55
Extreme 41.55
44.58
1 month 41.55
Extreme 41.55
48.56
Current year 41.55
Extreme 41.55
52.83
1 year 41.55
Extreme 41.55
79.8
3 years 30.43
Extreme 30.43
79.8
5 years 30.43
Extreme 30.43
122
10 years 23.19
Extreme 23.19
160.66
Manager TitleAgeSince
Chief Executive Officer 61 23/08/2013
Director of Finance/CFO 54 31/03/2017
Chief Tech/Sci/R&D Officer 69 01/02/2025
Director TitleAgeSince
Chairman 61 23/08/2013
Director/Board Member 48 22/01/2021
Director/Board Member 57 16/03/2017
Change 5d. change 1-year change 3-years change Capi.($)
-1.27%-5.54%-19.21%-20.33% 268.49Cr
-2.27%-16.10%-20.55%-38.52% 5.55TCr
+1.14%-2.00%+11.74%+60.29% 795.08Cr
-2.22%-23.69%-0.94%-24.22% 747.78Cr
-4.66%-18.11%-8.23%+56.46% 542.62Cr
-2.92%-12.52%-18.92%+94.28% 496.93Cr
+0.56%-1.02%+68.91%+43.57% 310.19Cr
+1.52%-10.25%+336.43%+710.47% 255.92Cr
-2.91%-5.22%+37.51%+43.01% 253.99Cr
+0.18%+1.50%-3.38%+5.03% 210.61Cr
Average -1.29%-6.27%+38.33%+93.00% 943.61Cr
Weighted average by Cap. -1.89%-11.55%-0.88%+10.09%

Financials

2025 *2026 *
Net sales 359.44Cr 52Cr 45Cr 41Cr 39Cr 71Cr 4.79TCr 74Cr 478.62Cr 191.93Cr 2.29TCr 195.36Cr 191.16Cr 8.23TCr 430.62Cr 62Cr 54Cr 49Cr 47Cr 85Cr 5.74TCr 88Cr 573.4Cr 229.94Cr 2.75TCr 234.05Cr 229.02Cr 9.86TCr
Net income 57Cr 8.27Cr 7.14Cr 6.44Cr 6.18Cr 11Cr 762.07Cr 12Cr 76Cr 31Cr 364.54Cr 31Cr 30Cr 1.31TCr 81Cr 12Cr 10Cr 9.15Cr 8.77Cr 16Cr 1.08TCr 17Cr 108.08Cr 43Cr 517.91Cr 44Cr 43Cr 1.86TCr
Net Debt 139.92Cr 20Cr 17Cr 16Cr 15Cr 27Cr 1.87TCr 29Cr 186.31Cr 75Cr 892.77Cr 76Cr 74Cr 3.2TCr 128.33Cr 19Cr 16Cr 14Cr 14Cr 25Cr 1.71TCr 26Cr 170.89Cr 69Cr 818.87Cr 70Cr 68Cr 2.94TCr
Logo Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co Ltd is a company mainly engaged in research, development, production and sales of innovative drugs for the treatment of malignant tumors. The Company's primary product is its self-developed icotinib hydrochloride (Conmana), a small molecule targeted anticancer drug used for the treatment of lung cancer. The Company is also engaged in promotional services, real estate leasing and other businesses.
Employees
1,961
Date Price Change Volume
09/26/09 43.45 ¥ -1.27% 40,90,000
06/26/06 44.01 ¥ +4.04% 56,22,726
05/26/05 42.30 ¥ +1.08% 43,15,519
04/26/04 41.85 ¥ -1.41% 42,99,442
03/26/03 42.45 ¥ -4.00% 62,14,534
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
43.45CNY
Average target price
63.79CNY
Spread / Average Target
+46.81%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. 300558 Stock
SPRING SALE -40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW